AbbVie Submits Anti-Inflammatory Drug Rinvoq for FDA, Europe Approval for Atopic Dermatitis

AbbVie (NYSE: ABBV) has taken an important step forward with one of its drug programs. The company announced Monday it has submitted its Rinvoq for approval to both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Rinvoq's submittal is for the treatment of moderate to severe atopic dermatitis, one of a series of inflammatory skin afflictions commonly known known as eczema, in adolescents and adults with moderate to severe forms of the disease.

Image source: Getty Images.

Continue reading

Source Fool.com